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A series of novel, pseudo-symmetrical diduoroketones which are highly potent inhibitors of the RN-1 protease (IC,, = 1.55-0.02 nM) were 
synthesized. These compounds also possess good antiviral activity by inhibition of the cytopathic effect of HIV-l,, in MI”*4 cells in vitro. 
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The human immunodeficiency virus (HIV), which is 
the causative agent of AIDS, encodes a protease which 
proteolytically processes the gag and gag-pol polypro- 
teins to form the mature proteins needed for the produc- 
tion of infectious viral particles [l]* The HIV-l protease 
is a member of the aspartic acid protease family and has 
been shown by X-ray ~~stallo~aph~ to be a C-2 sym- 
metrical dimer [2,3]. Replacement of the aspartic acid 
residues at the eatalytiic active site by site-directed mut- 
agenesis leads to the formation of immature, noninfec- 
tive virions [4,53. For this reason, the HIV protease is 
considered as an important target for the development 
of agents for the treatment of HIV infection. Towards 
this end, potent and selective inhibitors of HIV protease 
have been shown to inhibit the spread of HIV infection 
in vitro [6-141. 
We wish to report the synthesis and the biological 
evaluation of a novel series of pseudo-symmetrical dif- 
luoroketones which complements the symmetric, 
dimeric nature of the HIV-l protease. This series, which 
is represented by the generic structure 1 in Scheme 1, 
displays highly potent and selective activity against the 
HIV protease. The activities of these compounds 
against a series of other aspartic acid proteases uch as 
renin, pepsin or cathepsin D are at least 5 to 6 orders 
of magnitude less potent. The hydrolyzable amide bond 
of the -Phe(S,)-Pro(S&cleavage site of the substrate of 
~~r~e~pa~~~~~ a&&as.H.L. Sham, Abbott Laboratories, Anti-infec- 
tive Research, D47D, Abbott Park, IL 60064-3500, USA. 
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HIV protease is replaced by a non-hydroly~ble dif- 
luoroketone transition state mimic [ 151 in these inhib- 
itors. The P, and Pi side chains are kept identical (benzyl 
or isobutyl). The N-terminal blocking group repre- 
sented by T (see Scheme 1) can be benzyloxycarbonyl, 
2-pyridyl-carbamate, 2-pyridyl-urea or 2-pyridyl-sul- 
fonamide to provide a range of different aqueous solu- 
bilities to the inhibitors [16]. 
2. MATERIALS AND METHUDS 
The synthesis of the novel series of~~uoroketon~ represented by 
the generic structure I is outlined in Scheme 1. The addition of benay 
or isobutyl magnesium chloride to the known amide 2 [17] by the 
procedure of Weinreb [18] provided intermediate ketone 3. Oxime 
formation and catalytic hydrogenation provided the corresponding 
amine 4 (as a mixture of S and R configuration) which can be chroma- 
tographically separated and the S-amine was used for further reaction. 
The assignment of the stereochemistry was based on X-ray crystallog- 
raphy [17j. Opening of the oxazolidinone ring in 4 by basic hydrolysis 
and coupling with the protected L-valine fragment using DCC/HOBt 
coupling conditions provided compound 5. Oxidation of 5 with so- 
dium dichromate in acetic acid 119] provided the series of di- 
Auoroketones f. 
HIV-1 protease inhibition was measured by a fluorescence assay 
[20] using recombinant HIV-l protease, isolated as described previ- 
ously [21]+ Reactions were carried out at 30°C in reaction mixtures 
containing the following in a final volume of 300 ~1: 12.5 mM sodium 
acetate, pW 4.5; 1 M sodium chloride; 0.5 mM dithiothreitol; 0.5 
mg/ml bovine serum albumin; 1.3 PM fluorogenic substrate [20]. The 
fluorogenic substrate used is Dabcyl-Ser-Gln-Asp-Tyr-Pro-Ile-Val- 
Gln-EDANS wherein DABCYL = 4-(4dimethyIaminophenyl)azo- 
benzoic acid and EDANS = S-((2-aminoethyl)amino)- naphthalene-l- 
sulfonic acid. Xnhibitors, when present, were added from stock solu- 
tions made in d~ethylsulfo~~. The final dimet~yls~lfo~de concen- 
tration was adjusted to 2% in all cases. The reactions were initiated 
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Scheme 1. 
by the addition of approximately 1nM HIV-l protease and rates were 
determined by following the change in fluorescence intensity (excita- 
tion 340 nM, emission 490 nM) that accompanies the cleavage of the 
fluorogenic substrate. The 8 inhibition of enzyme activity in the pres- 
ence of inhibitor was determined by comparing inhibition rates with 
uninhibited control reactions. All IC,,, values were determined with a 
range of inhibitor concentrations using the relation IC,, = (100 : 8 
inhibition - 1) x inhibitor concentration. IC,, values should closely 
approximate true Ki values since the substrate concentration is much 
less than the Km determined previously [20]. 
2.3. Antiviral assays 
The in vitro antiviral activities of the difluoroketones i  determined 
by the inhibition of the cytopathic effect (CPE) of HIV-l,, in MT-4 
cells [22]. MT-4 cells (1 x 104) were infected with 10 TCID,, of HIV-l,, 
for 1 h, washed, and cultured at 37’C in RPM1 1640 + 10% FBS 
medium containing inhibitors (fluoroketones) in triplicate. Cytopathic 
effect and toxicity were monitored at day 5 by MTT uptake in 96-well 
microtiter plates using a Biotek model EL 320 at a wavelength of 
570-650 nM. The IC, and TCso values are shown in Table III. 
3. RESULTS AND DISCUSSION 
A series of pseudo-symmetrical difluoroketones that 
complements the C-2 symmetric nature of the HIV-l 
protease was synthesized and their inhibitory potency 
of recombinant HIV-l protease was determined. The 
results expressed in ICsO values are shown in Table I. 
These compounds were represented by the generic 
structure 1. Compound la can be considered the parent 
compound of the series with T = T, = benzyloxycar- 
bony& a common N-terminal protecting group for 
amino acids. The P, and Pi side chains are benzyl 
groups. It is a potent inhibitor of the HIV-l protease 
(IC,, = 0.1 nM). Changing the phenyl ring of the ben- 
zyloxycarbonyl protecting group to the 2-pyridyl (TJ 
increased the inhibitory potency by 5-fold. Changing 
the P, and Pi side chain from benzyl to isobutyl (lg) 
resulted in a decrease in potency of more than lo-fold. 
Variation of the linking group from a carbamate (T,, 
T,) to that of N-methyl-urea (T,); amide (T4); or sulfon- 
amide (TS) maintained the inhibitory potency below 1 
nM, while affording a variation of aqueous solubilities 
to the compounds. It is also important to note that all 
the compounds have high specificity against HIV-l. As 
shown in Table II, there are at least 5 to 6 orders of 
magnitude difference in inhibitory potency against 
HIV-l and a panel of other aspartic proteases. 
The in vitro antiviral activities of the difluoroketones 
against HIV- 1 3B in MT-4 cells are summarized in Table 
III. Compound la, though quite non-toxic to the cells, 
did not show any antiviral activity. This may be due to 
the highly lipophilic nature of la. The proper balance 
Table I 
Inhibition of HIV-1 protease by fluoroketones I
Compound no. T P, P; ICs0 (nM) 
la 
lb 
IC 
Id 
le 
If 
Ig 
T, 
T2 
T3 
T4 
T, 
T6 
T3 
phenyl 
phenyl 
phenyl 
phenyl 
phenyl 
phenyl 
isopropyl 
phenyl 0.10 
phenyl 0.02 
phenyl 0.40 
phenyl 0.33 
phenyl 0.24 
phenyl 0.05 
isopropyl 1.55 
For T, to T,, see Scheme 1 for structures. 
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Table II 
Inhibition of other aspartic acid proteases by fluoroketones 1 (IC,,) 
Compound no. 
la 
lb 
lc 
Id 
le 
If 
lg 
Renin 
>lOO PM 
>lOO PM 
>lOO PM 
>lOO PM 
>lOO PM 
>lOO PM 
>lOO PM 
Pepsin 
90 PM 
407 PM 
165 PM 
127 PM 
256 PM 
210 PM 
165 PM 
Cathepsin D 
>lOO FM 
94 PM 
77 PM 
>lOO PM 
>lOO PM 
>lOO PM 
98 PM 
between lipophilicity and hydrophilicity is important 
for antiviral activity because of cell membrane permea- 
bility. Compounds lb-lg, with 2-pyridyl groups incor- 
porated to increase their hydrophilicity, all showed 
good antiviral activity. The selectivity index (SI = TC,d 
I&,) which is an indication of the compounds’ effective- 
ness in inhibition of viral spread relative to their cell 
toxicity showed a fairly wide range. Compound lf, 
which inhibited the HIV-l protease with an IC,, = 0.05 
nM, exhibited a good antiviral activity (IC,, = 7 nM) 
and an excellent SI (>14,000). 
In conclusion, a novel series of pseudo-symmetrical 
difluoroketones which are highly potent inhibitors of 
the HIV-l protease and exhibit good antiviral activities 
in vitro are described. With further refinement, it is 
feasible to synthesize inhibitors with even greater po- 
tency and hopefully oral bioavailability. Inhibition of 
the retroviral HIV-l protease may provide a novel and 
potentially useful therapeutic approach for the treat- 
ment of AIDS and related diseases. 
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Table III 
Inhibition of HIV-l in vitro (MT-4 cells) by fluoroketones 1 
Compound no. 
la 
lb 
lc 
Id 
le 
If 
Ig 
AZT 
ICs, 01M) 
no effect 
0.04 
0.035 
0.05 
0.56 
0.007 
2.3 
0.016 
TC, NM) SI (TC&C,,) 
>lOO N.D. 
>lOO >2,500 
56 1,600 
>lOO >2,000 
42 75 
>lOO >14,285 
63 27 
>I0 >639 
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